Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A Review
Uterine spiral artery remodeling is essential for placental perfusion and fetal growth and, when impaired, results in placental ischemia and pregnancy complications, e.g., fetal growth restriction, preeclampsia, premature birth. Despite the high incidence of adverse pregnancies, current treatment op...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-08-01
|
Series: | Genes |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4425/12/8/1255 |
id |
doaj-2f6f32790abd47bd9b94004720ed786e |
---|---|
record_format |
Article |
spelling |
doaj-2f6f32790abd47bd9b94004720ed786e2021-08-26T13:47:07ZengMDPI AGGenes2073-44252021-08-01121255125510.3390/genes12081255Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A ReviewGerald J. Pepe0Eugene D. Albrecht1Department of Physiological Sciences, Eastern Virginia Medical School, Norfolk, VA 23507, USADepartments of Obstetrics/Gynecology/Reproductive Sciences and Physiology, University of Maryland School of Medicine, Baltimore, MD 21201, USAUterine spiral artery remodeling is essential for placental perfusion and fetal growth and, when impaired, results in placental ischemia and pregnancy complications, e.g., fetal growth restriction, preeclampsia, premature birth. Despite the high incidence of adverse pregnancies, current treatment options are limited. Accordingly, research has shifted to the development of gene therapy technologies that provide targeted delivery of “payloads” to the placenta while limiting maternal and fetal exposure. This review describes the current strategies, including placental targeting peptide-bound liposomes, nanoparticle or adenovirus constructs decorated with specific peptide sequences and placental gene promoters delivered via maternal IV injection, directly into the placenta or the uterine artery, as well as noninvasive site-selective targeting of regulating genes conjugated with microbubbles via contrast-enhanced ultrasound. The review also provides a perspective on the effectiveness of these technologies in various animal models and their practicability and potential use for targeted placental delivery of therapeutics and genes in adverse human pregnancies affected by placental dysfunction.https://www.mdpi.com/2073-4425/12/8/1255spiral artery remodelingpregnancy diseasesplacentapreeclampsiapeptide-mediated gene targetingtrophoblast-targeted nanoparticles |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Gerald J. Pepe Eugene D. Albrecht |
spellingShingle |
Gerald J. Pepe Eugene D. Albrecht Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A Review Genes spiral artery remodeling pregnancy diseases placenta preeclampsia peptide-mediated gene targeting trophoblast-targeted nanoparticles |
author_facet |
Gerald J. Pepe Eugene D. Albrecht |
author_sort |
Gerald J. Pepe |
title |
Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A Review |
title_short |
Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A Review |
title_full |
Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A Review |
title_fullStr |
Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A Review |
title_full_unstemmed |
Novel Technologies for Target Delivery of Therapeutics to the Placenta during Pregnancy: A Review |
title_sort |
novel technologies for target delivery of therapeutics to the placenta during pregnancy: a review |
publisher |
MDPI AG |
series |
Genes |
issn |
2073-4425 |
publishDate |
2021-08-01 |
description |
Uterine spiral artery remodeling is essential for placental perfusion and fetal growth and, when impaired, results in placental ischemia and pregnancy complications, e.g., fetal growth restriction, preeclampsia, premature birth. Despite the high incidence of adverse pregnancies, current treatment options are limited. Accordingly, research has shifted to the development of gene therapy technologies that provide targeted delivery of “payloads” to the placenta while limiting maternal and fetal exposure. This review describes the current strategies, including placental targeting peptide-bound liposomes, nanoparticle or adenovirus constructs decorated with specific peptide sequences and placental gene promoters delivered via maternal IV injection, directly into the placenta or the uterine artery, as well as noninvasive site-selective targeting of regulating genes conjugated with microbubbles via contrast-enhanced ultrasound. The review also provides a perspective on the effectiveness of these technologies in various animal models and their practicability and potential use for targeted placental delivery of therapeutics and genes in adverse human pregnancies affected by placental dysfunction. |
topic |
spiral artery remodeling pregnancy diseases placenta preeclampsia peptide-mediated gene targeting trophoblast-targeted nanoparticles |
url |
https://www.mdpi.com/2073-4425/12/8/1255 |
work_keys_str_mv |
AT geraldjpepe noveltechnologiesfortargetdeliveryoftherapeuticstotheplacentaduringpregnancyareview AT eugenedalbrecht noveltechnologiesfortargetdeliveryoftherapeuticstotheplacentaduringpregnancyareview |
_version_ |
1721193128085422080 |